D. Boral Capital Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $34.00 price objective on the stock.

NRXP has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research report on Wednesday, December 3rd. Zacks Research raised NRx Pharmaceuticals to a “hold” rating in a report on Wednesday, September 10th. Finally, Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.75.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP opened at $2.62 on Monday. The firm has a market cap of $77.55 million, a price-to-earnings ratio of -1.11 and a beta of 1.62. NRx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $6.01. The firm’s fifty day moving average price is $2.46 and its 200 day moving average price is $2.79.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $6.83 million. As a group, analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Anson Funds Management LP grew its position in shares of NRx Pharmaceuticals by 535.1% during the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after buying an additional 993,401 shares in the last quarter. Vanguard Group Inc. raised its holdings in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares in the last quarter. Geode Capital Management LLC boosted its stake in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after acquiring an additional 37,598 shares during the last quarter. Two Sigma Investments LP grew its holdings in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares in the last quarter. Finally, AdvisorShares Investments LLC grew its holdings in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after acquiring an additional 78,339 shares in the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.